Study Stopped
Sponsor decision to stop the study early and complete all required study close-out activities. This decision was made for business reasons unrelated to safety. None of the pre-specified efficacy endpoints were analyzed.
Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive
A Phase 3, Open-label, Multi-center, Single-arm Study to Assess Contraceptive Efficacy and Safety of the Nomegestrol Acetate + 17β-estradiol Combined Oral Contraceptive (OG-8175A) in Premenopausal Females Aged 14 to 35 Years (Inclusive)
1 other identifier
interventional
3,055
1 country
103
Brief Summary
The purpose of this study is evaluating Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive in Premenopausal Females Aged 14 to 35 Years (Inclusive).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Feb 2022
103 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 28, 2022
CompletedStudy Start
First participant enrolled
February 17, 2022
CompletedFirst Posted
Study publicly available on registry
March 3, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 12, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
January 26, 2024
CompletedResults Posted
Study results publicly available
November 21, 2025
CompletedNovember 21, 2025
September 1, 2025
1.9 years
January 28, 2022
January 12, 2025
November 10, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of Participants With On-treatment Pregnancies
Raw count of the number of pregnancies that occurred while participants were taking study drug
1 year
Secondary Outcomes (13)
Proportion of Participants With an Adverse Event (Regardless on Potential Relationship to Study Drug)
1 year
Proportion of Participants Who Prematurely Discontinue Study Drug Treatment
1 year
Percentage of Participants With On-treatment Pregnancies With at Least One Completed Cycle
1 year
Number of Cycles of Exposure Prior to Pregnancy
1 year
Number of Participants With a Pregnancy, Based on Baseline BMI Categories (<30 kg/m2, ≥30 kg/m2)
1 year
- +8 more secondary outcomes
Study Arms (1)
Nomegestrol Acetate + 17β-estradiol (NOMAC-E2; OG-8175A)
EXPERIMENTALThe NOMAC-E2 COC active tablets contain 2.5 mg NOMAC and 1.5 mg E2 and will be used in a 24/4 regimen, i.e., 28-day cycles with 24 days of active tablet intake followed by 4 days of placebo tablet intake.
Interventions
Dosage Formulation: Film-coated Tablet Unit Dose Strength: Nomegestrol acetate (NOMAC) 2.5 mg and estradiol (E2) 1.5 mg; Each blister strip contains 28 tablets: 24 tablets with the active drug (number 1 to 24) and 4 tablets with placebo (number 25 to 28). Dosing Instructions: oral. Take 1 tablet daily at about the same time as directed.
Eligibility Criteria
You may qualify if:
- Postmenarcheal, premenopausal female aged 14 to 35 years (inclusive)
- At risk for pregnancy (including heterosexual vaginal intercourse at least once a month and not sterilized).
- No desire for pregnancy within 1 year following screening and is not intending to use any other form of contraception
- Good physical and mental health
- History of regular menstrual cycles prior to the use of any hormonal contraceptive.
- Able and willing to adhere study procedures
You may not qualify if:
- Current known or expected pregnancy
- History of subfertility or infertility
- Less than 2 normal menstrual cycles following recent pregnancy of gestational age
- Breastfeeding within 2 months of study drug start
- Known HIV infection
- Untreated gonorrhea, chlamydia, or trichomonas
- abnormal PAP within timeline of standard of care guidelines
- Unexplained/unresolved abnormal vaginal bleeding
- Presence/history of VTE, ATE, transient ischemic attack, angina pectoris, or claudication
- Higher risk for VTE
- Uncontrolled or severe hypertension
- Severe dyslipoproteinemia
- History of migraine with aura or focal neurological symptoms
- Diabetes mellitus (with either end-organ involvement or \>20 years duration)
- Multiple cardiovascular risk factors
- +12 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Organon and Colead
- Iqvia Pty Ltdcollaborator
Study Sites (103)
Alabama Clinical Therapeutics, LLC
Birmingham, Alabama, 35235, United States
SEC Clinical Research
Dothan, Alabama, 36305, United States
Alliance for Multispecialty Research, LLC
Mobile, Alabama, 36608, United States
Velocity Clinical Research
Mobile, Alabama, 36608, United States
Mesa Obstetricians and Gynecologists
Mesa, Arizona, 85206, United States
Desert Clinical Research, LLC/CCT Research
Mesa, Arizona, 85213, United States
Velocity Clinical Research - Phoenix
Phoenix, Arizona, 85006, United States
Precision Trials AZ, LLC
Phoenix, Arizona, 85032, United States
Alliance for Multispecialty Research
Tempe, Arizona, 85281, United States
Noble Clinical Research
Tucson, Arizona, 85704, United States
Eclipse Clinical Research
Tucson, Arizona, 85745, United States
Gardens Medical Center / Alliance Research Institute
Bell Gardens, California, 90201, United States
Alliance Research Institute, LLC
Canoga Park, California, 91304, United States
Advanced Investigative Medicine, Inc
Hawthorne, California, 90250, United States
Marvel Clinical Research
Huntington Beach, California, 92647, United States
Om Research LLC
Lancaster, California, 93534, United States
Empire Clinical Research
Pomona, California, 91767, United States
WR-Women's Health Care Research, LLC
San Diego, California, 92111, United States
WR-Medical Center For Clinical Research - San Diego
San Diego, California, 92120, United States
Velocity Clinical Research
Denver, Colorado, 80209, United States
Physicians' Research Options / Red Rocks OB/GYN
Lakewood, Colorado, 80228, United States
CMR of Greater New Haven, LLC
Hamden, Connecticut, 06517, United States
Alliance for Multispecialty Research, LLC
Coral Gables, Florida, 33134, United States
Universal Axon Clinical Research, LLC
Doral, Florida, 33166, United States
Alliance for Multispecialty Research, LLC
Fort Myers, Florida, 33912, United States
Altus Research, Inc.
Lake Worth, Florida, 33461, United States
Accel Research Sites - St. Petersburg Clinical Research Unit
Largo, Florida, 33777, United States
OB-GYN Associates of Mid-Florida, PA
Leesburg, Florida, 34748, United States
Avantis Clinical Research, LLC
Miami, Florida, 33155, United States
Miami Clinical Research
Miami, Florida, 33155, United States
Admed Research, LLC
Miami, Florida, 33173, United States
Genoma Research Group, Inc.
Miami, Florida, 33173, United States
Spotlight Research Center, LLC
Miami, Florida, 33176, United States
New Age Medical Research Corporation
Miami, Florida, 33186, United States
Quantum Clinical Trials
Miami Beach, Florida, 33140, United States
Quality Research of South Florida
Miami Lakes, Florida, 33016, United States
Healthcare Clinical Data, Inc.
North Miami, Florida, 33161, United States
Sensible Healthcare LLC
Ocoee, Florida, 34761, United States
Innovation Medical Research Center
Palmetto Bay, Florida, 33157, United States
Clinical Research Center of Florida
Pompano Beach, Florida, 33060, United States
R & B Medical Center LLC
Tampa, Florida, 33614, United States
Comprehensive Clinical Research, LLC
West Palm Beach, Florida, 33409, United States
Agile Clinical Research Trials, LLC
Atlanta, Georgia, 30328, United States
Infinite Clinical Trials
Morrow, Georgia, 30260, United States
Javara Inc / Privia Medical Group Georgia, LLC
Pooler, Georgia, 31322, United States
WR-Mount Vernon Clinical Research, LLC
Sandy Springs, Georgia, 30328, United States
Leavitt Clinical Research
Idaho Falls, Idaho, 83404, United States
Women's Healthcare Associates P.A.
Idaho Falls, Idaho, 83404, United States
The Iowa Clinic
Ankeny, Iowa, 50023, United States
Alliance for Multispecialty Research, LLC
El Dorado, Kansas, 67042, United States
Alliance for Multispecialty Research, LLC
Newton, Kansas, 67114, United States
Alliance for Multispecialty Research, LLC
Wichita, Kansas, 67205, United States
Alliance for Multispecialty Research, LLC
Wichita, Kansas, 67207, United States
Alliance for Multispecialty Research, LLC - Lexington
Lexington, Kentucky, 40509, United States
Velocity Clinical Research - Covington
Covington, Louisiana, 70433, United States
Velocity Clinical Research
Lafayette, Louisiana, 70508, United States
Southern Clinical Research Associates
Metairie, Louisiana, 70001, United States
Velocity Clinical Research
Metairie, Louisiana, 70006, United States
Alliance for Multispecialty Research, LLC
New Orleans, Louisiana, 70119, United States
Velocity Clinical Research
Slidell, Louisiana, 70458, United States
Continental Clinical Solutions
Towson, Maryland, 21204, United States
NECCR PrimaCare Research, LLC
Fall River, Massachusetts, 02721, United States
Exordia Medical Research, Inc
Fall River, Massachusetts, 02723, United States
Velocity Clinical Research
Gulfport, Mississippi, 39503, United States
Alliance for Multispecialty Research, LLC
Kansas City, Missouri, 64114, United States
Velocity Clinical Research
Grand Island, Nebraska, 68803, United States
Velocity Clinical Research
Hastings, Nebraska, 68901, United States
Velocity Clinical Research
Omaha, Nebraska, 68134, United States
Jubilee Clinical Research, Inc
Las Vegas, Nevada, 89106, United States
Essential Women's Health Associates
Las Vegas, Nevada, 89113, United States
Alliance for Multispecialty Research, LLC
Las Vegas, Nevada, 89119, United States
Planned Parenthood of Northern, Central, and Southern New Jersey
Perth Amboy, New Jersey, 08861, United States
Albuquerque Clinical Trials, Inc
Albuquerque, New Mexico, 87102, United States
Bosque Women's Care
Albuquerque, New Mexico, 87109, United States
Meridian Clinical Research, LLC
Vestal, New York, 13850, United States
Carolina Women's Research and Wellness Center
Durham, North Carolina, 27713, United States
Carolina Institute For Clinical Research
Fayetteville, North Carolina, 28303, United States
M3 Wake Research, Inc
Raleigh, North Carolina, 27612, United States
University of Cincinnati Physicians
Cincinnati, Ohio, 45267, United States
OB/GYN Associates of Erie
Erie, Pennsylvania, 16507, United States
Clinical Research of Philadelphia, LLC
Philadelphia, Pennsylvania, 19114, United States
Venus Gynecology, LLC
Myrtle Beach, South Carolina, 29572, United States
Chattanooga Medical Research, LLC
Chattanooga, Tennessee, 37404, United States
Alliance for Multispecialty Research, LLC
Knoxville, Tennessee, 37909, United States
New Phase Research & Development
Knoxville, Tennessee, 37909, United States
WR-Medical Research Center of Memphis
Memphis, Tennessee, 38120, United States
Tekton Research, Inc
Austin, Texas, 78705, United States
Helios Clinical Research
Burleson, Texas, 76028, United States
Cedar Health Research
Dallas, Texas, 75251, United States
Helios Clinical Research
Fort Worth, Texas, 76104, United States
Javara Inc
Houston, Texas, 77054, United States
Accurate Clinical Research, Inc
Houston, Texas, 77065, United States
Clinical Trial Network
Houston, Texas, 77074, United States
Texas Health Care, PLLC d/b/d Privia Medical Group - North Texas
Rowlett, Texas, 75088, United States
Tekton Research, Inc
San Antonio, Texas, 78229, United States
Javara Research
Stephenville, Texas, 76401, United States
Javara Inc
Sugar Land, Texas, 77478, United States
Helios Clinical Research - Weatherford
Weatherford, Texas, 76086, United States
Wasatch Clinical Research
Salt Lake City, Utah, 84107, United States
Javara Research
Forest, Virginia, 24551, United States
Alliance for Multispecialty Research, LLC
Norfolk, Virginia, 23502, United States
Tidewater Clinical Research
Norfolk, Virginia, 23502, United States
Seattle Clinical Research Center
Seattle, Washington, 98105, United States
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Limitations and Caveats
Due to the study's early discontinuation (for business reasons), a small number of participants completed the study prior to its discontinuation, limiting the data available for efficacy outcome measures.
Results Point of Contact
- Title
- Clinical Lead, Late-Stage Clinical Development
- Organization
- Organon and Co
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- NA
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 28, 2022
First Posted
March 3, 2022
Study Start
February 17, 2022
Primary Completion
January 12, 2024
Study Completion
January 26, 2024
Last Updated
November 21, 2025
Results First Posted
November 21, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will not share